| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Rosa Fernandes | Q47503161 |
| Flávio Reis | Q38545312 | ||
| Cristina Mega | Q85378759 | ||
| Eugénia Carvalho | Q42516249 | ||
| Edite Teixeira De Lemos | Q64190488 | ||
| P2093 | author name string | Frederico Teixeira | |
| Ricardo Godinho | |||
| P2860 | cites work | Positional cloning of the mouse obese gene and its human homologue | Q22251285 |
| A role for glucagon-like peptide-1 in the central regulation of feeding | Q24314317 | ||
| Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies | Q24568148 | ||
| Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors | Q24598747 | ||
| Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin | Q24642412 | ||
| Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease | Q24647189 | ||
| Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study | Q24652963 | ||
| Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*. | Q46773118 | ||
| Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes | Q46804059 | ||
| Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study | Q46850405 | ||
| Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study | Q46885175 | ||
| Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes | Q46953451 | ||
| Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses | Q46955963 | ||
| Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. | Q46975079 | ||
| Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action | Q47744392 | ||
| Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats | Q47873900 | ||
| Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes | Q47994395 | ||
| Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. | Q48866872 | ||
| Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats | Q48905629 | ||
| Different enzyme activities in coronary capillary endothelial cells. | Q50532021 | ||
| Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. | Q50991893 | ||
| Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. | Q51244259 | ||
| Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. | Q51355802 | ||
| The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. | Q51355945 | ||
| Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. | Q51359217 | ||
| Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. | Q51361433 | ||
| Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. | Q51365744 | ||
| Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes. | Q51369410 | ||
| Pharmacology, physiology, and mechanisms of incretin hormone action | Q27021545 | ||
| Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders | Q28116286 | ||
| The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness | Q28216072 | ||
| Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes | Q28262769 | ||
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 | ||
| Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses | Q28285795 | ||
| Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial | Q28286240 | ||
| Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 | ||
| Alogliptin after acute coronary syndrome in patients with type 2 diabetes | Q28297690 | ||
| Pancreatic safety of incretin-based drugs--FDA and EMA assessment | Q28308049 | ||
| The Physiology of Glucagon-like Peptide 1 | Q28373115 | ||
| Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms | Q28535415 | ||
| Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats | Q28578709 | ||
| Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion | Q28588815 | ||
| Global estimates of the prevalence of diabetes for 2010 and 2030 | Q29547218 | ||
| Biology of incretins: GLP-1 and GIP | Q29617302 | ||
| The future role of gut hormones in the treatment of obesity | Q30357431 | ||
| The entero-insular axis: implications for human metabolism. | Q30365939 | ||
| Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. | Q30368546 | ||
| Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model | Q30513617 | ||
| Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes | Q33209301 | ||
| Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. | Q33368655 | ||
| Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis | Q33562131 | ||
| Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks | Q33603409 | ||
| Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes | Q33603551 | ||
| Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus | Q33608090 | ||
| GIP and GLP-1, the two incretin hormones: Similarities and differences | Q33609502 | ||
| Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential | Q33751145 | ||
| Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat) | Q34003019 | ||
| Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study | Q34035766 | ||
| Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study | Q34044817 | ||
| Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus | Q34135837 | ||
| Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis | Q34237350 | ||
| Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. | Q37973413 | ||
| Review of linagliptin for the treatment of type 2 diabetes mellitus | Q37996131 | ||
| Update on incretin hormones | Q38006504 | ||
| Linagliptin: a review of its use in the management of type 2 diabetes mellitus | Q38036742 | ||
| Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes | Q38047614 | ||
| The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists | Q38088195 | ||
| Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety | Q38126945 | ||
| Gut hormones as therapeutic agents in treatment of diabetes and obesity. | Q38141445 | ||
| The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits | Q38145277 | ||
| Incretin actions beyond the pancreas: lessons from knockout mice | Q38149622 | ||
| Physiology and pathophysiology of incretins in the kidney | Q38164490 | ||
| The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? | Q38174491 | ||
| The role of incretin-based therapies in prediabetes: a review | Q38199251 | ||
| Canagliflozin: a review of its use in patients with type 2 diabetes mellitus | Q38212007 | ||
| The potential for renoprotection with incretin-based drugs | Q38227648 | ||
| Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors | Q38248682 | ||
| The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. | Q38253620 | ||
| Dipeptidyl peptidase-4 inhibitors in progressive kidney disease | Q38270324 | ||
| Inhibition of gastric inhibitory polypeptide signaling prevents obesity | Q38288099 | ||
| Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. | Q38300997 | ||
| Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. | Q38301976 | ||
| Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease | Q38436685 | ||
| The incretin concept today | Q39227026 | ||
| A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. | Q39544576 | ||
| Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet | Q39599495 | ||
| Gastrointestinal Hormones and the Control of Insulin Secretion | Q39725580 | ||
| Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice | Q39797395 | ||
| New developments in the incretin concept | Q39832287 | ||
| Amylin uncovered: a review on the polypeptide responsible for type II diabetes. | Q39846208 | ||
| Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways | Q40652421 | ||
| Synthetic Gastric Inhibitory Polypeptide Stimulatory Effect on Insulin and Glucagon Secretion in the Rat | Q40764707 | ||
| Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling | Q40784305 | ||
| Functional GIP receptors are present on adipocytes | Q41011734 | ||
| Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1. | Q41167245 | ||
| The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action | Q41281439 | ||
| Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line | Q41694915 | ||
| GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. | Q41965240 | ||
| Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials | Q41983958 | ||
| New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins | Q42078124 | ||
| The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects | Q42436041 | ||
| Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers | Q46350665 | ||
| The [pre-] history of the incretin concept | Q46393857 | ||
| Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus | Q46466735 | ||
| The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. | Q46493432 | ||
| Incretin and islet hormonal responses to fat and protein ingestion in healthy men. | Q46494673 | ||
| Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes | Q46654955 | ||
| Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension | Q46691868 | ||
| Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial | Q46701530 | ||
| Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice | Q46734172 | ||
| Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea | Q46745719 | ||
| Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study | Q83386003 | ||
| Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes | Q83389700 | ||
| Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*) | Q84358203 | ||
| DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes | Q84956767 | ||
| Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat | Q86037160 | ||
| Glucagonlike Peptide 1-based drugs and pancreatitis: clarity at last, but what about pancreatic cancer? | Q86283759 | ||
| C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes | Q86968195 | ||
| Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy | Q87262274 | ||
| Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease | Q88013961 | ||
| Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses | Q93538767 | ||
| Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes | Q94681234 | ||
| Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes | Q42796078 | ||
| Saxagliptin (Onglyza): new inhibitor of the dipeptidylpeptidase-4 for the oral treatment of type 2 diabetes | Q42802918 | ||
| Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes | Q42824310 | ||
| Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade | Q42831723 | ||
| Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus | Q42914097 | ||
| Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial | Q42999172 | ||
| A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study | Q43034890 | ||
| Hydrophilic residues surrounding the S1 and S2 pockets contribute to dimerisation and catalysis in human dipeptidyl peptidase 8 (DP8). | Q43035089 | ||
| Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial | Q43086322 | ||
| Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes | Q43087481 | ||
| Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes | Q43187035 | ||
| Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes | Q43195702 | ||
| Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. | Q43224233 | ||
| Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors | Q43244727 | ||
| Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia | Q43275817 | ||
| Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas | Q43276184 | ||
| Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes | Q43286552 | ||
| Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes | Q43467002 | ||
| Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: a pilot study | Q43475498 | ||
| Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs | Q43651817 | ||
| Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients | Q43705651 | ||
| Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers | Q43913912 | ||
| Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes | Q43972608 | ||
| GLP-1 based agents and acute pancreatitis : drug safety falls victim to the three monkey paradigm | Q44017411 | ||
| Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis | Q44103908 | ||
| Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients | Q44110180 | ||
| Gastric inhibitory polypeptide does not inhibit gastric emptying in humans | Q44215026 | ||
| Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes | Q44403823 | ||
| Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: role of GLP-1 and GLP-1 receptor | Q44412631 | ||
| Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats | Q44432573 | ||
| Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. | Q44442300 | ||
| Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia | Q44452284 | ||
| Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes | Q44467078 | ||
| Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance | Q44887107 | ||
| Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury | Q45199143 | ||
| Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes | Q45218410 | ||
| Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes | Q45250947 | ||
| Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate | Q45361069 | ||
| Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. | Q45935416 | ||
| Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. | Q45974572 | ||
| Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus | Q46075201 | ||
| Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin | Q46120204 | ||
| Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy | Q46173840 | ||
| Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus | Q46177613 | ||
| Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea | Q46189794 | ||
| Protection of exendin-4 analogue in early experimental diabetic retinopathy | Q46196926 | ||
| KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes | Q46218694 | ||
| Intracerebroventricular infusion of neuropeptide Y increases glucose dependent-insulinotropic peptide secretion in the fasting conscious dog. | Q46249697 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes | Q37193717 | ||
| Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. | Q37244738 | ||
| The incretin system and its role in type 2 diabetes mellitus | Q37266863 | ||
| Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction | Q37277960 | ||
| Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study | Q37331159 | ||
| Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes | Q37393380 | ||
| Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. | Q37501142 | ||
| Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes | Q37598881 | ||
| Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals | Q37725539 | ||
| Pharmacokinetics of dipeptidylpeptidase-4 inhibitors | Q37768821 | ||
| Alogliptin: a review of its use in the management of type 2 diabetes mellitus | Q37794971 | ||
| Vildagliptin: a review of its use in type 2 diabetes mellitus | Q37801906 | ||
| Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review | Q37813161 | ||
| Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience. | Q37837059 | ||
| A cohort study of acute pancreatitis in relation to exenatide use. | Q37841739 | ||
| Alogliptin for the treatment of type 2 diabetes | Q37856745 | ||
| Sitagliptin: a review | Q37886184 | ||
| Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation. | Q37912391 | ||
| Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis | Q34265490 | ||
| DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat | Q34270500 | ||
| The biology of incretin hormones | Q34499706 | ||
| Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis | Q34530843 | ||
| Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. | Q34560590 | ||
| Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor | Q34579106 | ||
| The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. | Q34585388 | ||
| Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. | Q34589793 | ||
| Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies | Q34627077 | ||
| Clinical pharmacokinetics and pharmacodynamics of linagliptin. | Q34638128 | ||
| Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis | Q34648377 | ||
| Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes | Q34862358 | ||
| The role of gut hormones in glucose homeostasis | Q35251016 | ||
| Enhancing Incretin Action for the Treatment of Type 2 Diabetes | Q35545683 | ||
| Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). | Q35607330 | ||
| Entero-insular axis and diabetes mellitus | Q35663295 | ||
| Physiology of incretins in health and disease | Q35760279 | ||
| Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus | Q35824086 | ||
| Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans | Q35844598 | ||
| Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes | Q35961969 | ||
| Glucose-dependent insulinotropic polypeptide as a regulator of beta cell function and fate | Q36012483 | ||
| Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes | Q36293659 | ||
| Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study | Q36420499 | ||
| Diabetes impairs stem cell and proangiogenic cell mobilization in humans | Q36720330 | ||
| Incretins and other peptides in the treatment of diabetes | Q36722459 | ||
| Incretins: a new treatment option for type 2 diabetes? | Q36767435 | ||
| Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes | Q36779756 | ||
| Role of protein kinase C, PI3-kinase and tyrosine kinase in activation of MAP kinase by glucose and agonists of G-protein coupled receptors in INS-1 cells | Q36782168 | ||
| Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency | Q36782645 | ||
| Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism | Q36796024 | ||
| Deficiency of glucose-dependent insulinotropic polypeptide receptor prevents ovariectomy-induced obesity in mice | Q36846114 | ||
| Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats | Q36946065 | ||
| GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism | Q37078997 | ||
| A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents. | Q51373947 | ||
| Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. | Q51376314 | ||
| The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. | Q51376983 | ||
| Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. | Q51381776 | ||
| Sitagliptin reduces albuminuria in patients with type 2 diabetes. | Q51382706 | ||
| Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. | Q51382898 | ||
| Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. | Q51385774 | ||
| Incretin-based Therapies for Type 2 Diabetes. | Q51456897 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. | Q51468797 | ||
| Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. | Q51471806 | ||
| Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. | Q51475385 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. | Q51478110 | ||
| Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. | Q51478140 | ||
| Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. | Q51479112 | ||
| Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. | Q51479779 | ||
| Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. | Q51484657 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. | Q51484788 | ||
| Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. | Q51484798 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. | Q51489068 | ||
| Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. | Q51492143 | ||
| Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. | Q51554261 | ||
| Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. | Q51563042 | ||
| Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. | Q51601217 | ||
| Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. | Q51745935 | ||
| DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy. | Q53083196 | ||
| The discovery of glucagon-like peptide 1. | Q53304399 | ||
| Filling the void of well-trained occupational medicine physicians: a challenge for the 1990s. | Q54672647 | ||
| Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in mice | Q57591390 | ||
| Reduced Incretin Effect in Type 2 Diabetes | Q58168459 | ||
| GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet | Q58448374 | ||
| GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans | Q58448859 | ||
| Glucagon-Like Peptide I Enhances the Insulinotropic Effect of Glibenclamide in NIDDM Patients and in the Perfused Rat Pancreas | Q58449061 | ||
| Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects | Q58449089 | ||
| Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide | Q61836852 | ||
| Dipeptidyl peptidase-IV inhibition prevents blood–retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats | Q61952009 | ||
| Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model | Q61952011 | ||
| Molecular characterization of dipeptidyl peptidase activity in serum | Q62660688 | ||
| Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels | Q67275679 | ||
| Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas | Q67442154 | ||
| Gastric inhibitory polypeptide enhancement of the insulin effect on fatty acid incorporation into adipose tissue in the rat | Q70304238 | ||
| A Gastric Inhibitory Polypeptide. I. The Amino Acid Composition and the Tryptic Peptides | Q71761356 | ||
| Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose | Q73936311 | ||
| NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE | Q76819524 | ||
| Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes | Q80349827 | ||
| Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats | Q82186212 | ||
| The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells | Q83343192 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hyperglycemia | Q271993 |
| dipeptidyl peptidase-4 inhibitors | Q419770 | ||
| type 2 diabetes | Q3025883 | ||
| mechanism of action | Q3271540 | ||
| carbohydrate | Q11358 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 806979 | |
| P577 | publication date | 2015-05-17 | |
| P1433 | published in | Journal of Diabetes Research | Q26841822 |
| P1476 | title | The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? | |
| P478 | volume | 2015 |
| Q36256469 | A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes |
| Q26785454 | Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes |
| Q64971834 | Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes. |
| Q92304204 | Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes |
| Q96228404 | Effects of Spirulina platensis on insulin secretion, DPP-IV activity and both carbohydrate digestion and absorption indicate potential as an adjunctive therapy for diabetes |
| Q36192977 | Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent |
| Q90426904 | Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria |
| Q42380223 | Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance |
| Q33593471 | Protein Digestion-Derived Peptides and the Peripheral Regulation of Food Intake |
| Q42876331 | Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes |
| Q38820260 | The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond |
| Q61814333 | Therapeutic Options Targeting Oxidative Stress, Mitochondrial Dysfunction and Inflammation to Hinder the Progression of Vascular Complications of Diabetes |
Search more.